Sezary Syndrome: Clinical Trials

128 trials for Sezary Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

82 completed, 23 terminated, 6 unknown, 5 active not recruiting. 128 Phase 2, 31 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2128Completed 82, Terminated 23, Unknown 6, Active not recruiting 5, Withdrawn 5, Recruiting 4, Not yet recruiting 3
Phase 131Completed 21, Terminated 6, Not yet recruiting 2, Recruiting 1, Withdrawn 1
Phase 32Completed 1, Terminated 1

Follow Sezary Syndrome: new trials by email Literature Review of Sezary Syndrome trials Research Report on Sezary Syndrome

Trials (filtered) newest first · largest first

All 128 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia
Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia
Phase 2Not yet recruitingWashington University School of Medicine242026-12-312026-11-05
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
Phase 1 / Phase 2Not yet recruitingMedsyn Biopharma, LLC752026-11-012026-10-27
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Aclarubicin, Cyclophosphamide, Vincristine - Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed
Phase 1 / Phase 2Not yet recruitingShanghai Jiao Tong University School of Medicine372026-03-302026-04-17
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
PTX-100 - CTCL
Phase 2RecruitingPrescient Therapeutics, Ltd.1152025-03-282026-09-09
Ritlecitinib in CTCL
Ritlecitinib - CTCL, Mycosis Fungoides
Phase 2TerminatedIcahn School of Medicine at Mount Sinai72023-05-172025-07-18
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment - Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Phase 2RecruitingCity of Hope Medical Center342022-10-192026-09-02
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Gemcitabine, Pembrolizumab - Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center142021-10-012026-11-02
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment - Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2TerminatedEmory University52021-04-212024-08-13
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)82021-04-062025-10-16
Study of Photopheresis in the Treatment of Erythrodermic MF and SS
Methoxsalen, THERAKOS CELLEX Photopheresis System - Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
Phase 2WithdrawnEuropean Organisation for Research and Treatment of Cancer - EORTC2020-12-012021-09-08
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Letermovir - B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia
Phase 2CompletedOhio State University Comprehensive Cancer Center62020-09-152025-02-28
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Mogamulizumab, LD TSEBT - Sezary Syndrome, Mycosis Fungoides
Phase 2RecruitingStanford University302020-03-302026-07-01
Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
Pembrolizumab - Mycosis Fungoides, Sezary Syndrome
Phase 2CompletedMayo Clinic92020-02-042025-08-29
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
IPH4102 - Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous
Phase 2CompletedInnate Pharma1702019-05-222026-04-29
A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)
Pembrolizumab, Radiotherapy - Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome
Phase 2Active not recruitingUniversity College, London462019-01-152024-12-09
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
Atezolizumab - Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
Phase 2TerminatedEuropean Organisation for Research and Treatment of Cancer - EORTC262018-09-242024-02-22
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
brentuximab vedotin - Mycosis Fungoides, Lymphomatoid Papulosis
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center512018-07-032026-11-06
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
Doxycycline monohydrate - Cutaneous T-cell Lymphoma, Mycosis Fungoides
Phase 2TerminatedRochester General Hospital12018-02-062021-04-27
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma
Phase 2CompletedNational Cancer Institute (NCI)282017-12-142023-10-25
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive
Phase 2Active not recruitingNational Cancer Institute (NCI)682017-09-272026-11-18

Showing 20 of 128. Sign in to see all of them.

Narrower conditions

Mycosis Fungoides (125)  ·  Lymphoma, T-Cell, Cutaneous (113)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (67)  ·  Lymphoma, B-Cell, Marginal Zone (67)  ·  Lymphoma, Follicular (67)  ·  Lymphoma, Large B-Cell, Diffuse (66)  ·  Lymphoma, Non-Hodgkin (66)  ·  Lymphoma, Mantle-Cell (64)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (63)  ·  Hodgkin Disease (61)  ·  Lymphoma, Large-Cell, Immunoblastic (59)  ·  Burkitt Lymphoma (58)  ·  Lymphoma (50)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (50)

Broader conditions

Hemic and Lymphatic Diseases (128)  ·  Immune System Diseases (128)  ·  Immunoproliferative Disorders (128)  ·  Lymphatic Diseases (128)  ·  Neoplasms by Histologic Type (128)  ·  Neoplasms (124)  ·  Lymphoma, T-Cell (122)  ·  Lymphoproliferative Disorders (120)  ·  Lymphoma (78)  ·  Hematologic Diseases (76)  ·  Leukemia, Lymphoid (76)  ·  Disease Attributes (71)  ·  Pathologic Processes (71)  ·  Pathological Conditions, Signs and Symptoms (71)  ·  Lymphoma, B-Cell (69)

Interventions

fludarabine phosphate (22)  ·  Mycophenolic Acid (19)  ·  Peripheral Blood Stem Cell Transplantation (18)  ·  Tacrolimus (17)  ·  Cyclophosphamide (16)  ·  Whole-Body Irradiation (16)  ·  Cyclosporine (14)  ·  Antilymphocyte Serum (12)  ·  Busulfan (12)  ·  Methotrexate (12)  ·  Radiotherapy (8)  ·  Rituximab (7)  ·  Alemtuzumab (6)  ·  Etoposide (6)  ·  Bexarotene (5)

Sponsors

Fred Hutchinson Cancer Center (19)  ·  National Cancer Institute (NCI) (13)  ·  Northwestern University (10)  ·  Mayo Clinic (7)  ·  European Organisation for Research and Treatment of Cancer - EORTC (5)  ·  Case Comprehensive Cancer Center (4)  ·  City of Hope Medical Center (4)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  Roswell Park Cancer Institute (3)  ·  UNC Lineberger Comprehensive Cancer Center (3)  ·  Genmab (2)  ·  Herbert Irving Comprehensive Cancer Center (2)  ·  Jonsson Comprehensive Cancer Center (2)  ·  M.D. Anderson Cancer Center (2)  ·  Novartis Pharmaceuticals (2)

Countries

United States (109)  ·  Italy (11)  ·  Germany (8)  ·  Switzerland (8)  ·  France (7)  ·  Belgium (5)  ·  United Kingdom (5)  ·  Austria (4)  ·  Spain (4)  ·  Australia (3)  ·  Canada (2)  ·  Poland (2)  ·  Argentina (1)  ·  China (1)  ·  Finland (1)

Top investigators

Timothy M. Kuzel, MD (4)  ·  Brenda Sandmaier (3)  ·  Ajay Gopal (2)  ·  Alison Moskowitz, MD (2)  ·  David G. Savage, MD (2)  ·  David Maloney (2)  ·  Madeleine Duvic, MD (2)  ·  Robert Knobler (2)  ·  Steven M. Horwitz, MD (2)  ·  Thomas C. Shea, MD (2)  ·  Thomas E. Witzig, MD (2)  ·  Tim Illidge (2)  ·  Youn H Kim, MD (2)  ·  Adam Petrich, MD (1)

Results publications

PMID 32499241, PMID 32632956, PMID 12543862, PMID 15107815, PMID 17515522, PMID 18327587, PMID 19170225, PMID 19199905, PMID 19826128, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 21135857, PMID 21355097, PMID 22981498, PMID 23045580, PMID 24241210, PMID 24285015, PMID 24307695, PMID 24335103, PMID 25795722, PMID 25891346, PMID 25921059, PMID 26195720, PMID 26210442, PMID 26213141, PMID 26764356, PMID 28199478, PMID 28264616, PMID 28314788, PMID 31532724, PMID 31689242, PMID 32269142, PMID 32941647, PMID 33072126, PMID 33236943, PMID 34795254, PMID 37327113, PMID 38664936, PMID 39951620, PMID 41651641

NIH funding

P30CA015704 (9), P01CA018029 (3), P30CA008748 (3), P30CA015083 (3), P30CA043703 (3), 2018 (2), P01CA078902 (2), P30CA016086 (2), P30CA033572 (2), P30CA060553 (2), U01CA154967 (2), 2004 (1), 2016 (1), 2017 (1), 2023 (1)